INVENTISBIO SHANGHAI LTD has a total of 30 patent applications. It increased the IP activity by 150.0%. Its first patent ever was published in 2015. It filed its patents most often in WIPO (World Intellectual Property Organization), United States and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals and organic fine chemistry are CTI BIOPHARMA CORP, KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LTD and RENEXXION LLC.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 10 | |
#2 | United States | 8 | |
#3 | EPO (European Patent Office) | 3 | |
#4 | China | 2 | |
#5 | Israel | 2 | |
#6 | Republic of Korea | 2 | |
#7 | Canada | 1 | |
#8 | Hong Kong | 1 | |
#9 | Taiwan | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry |
# | Name | Total Patents |
---|---|---|
#1 | Jiang Yueheng | 28 |
#2 | Dai Xing | 20 |
#3 | Liu Yanqin | 7 |
#4 | Wang Zhenwu | 6 |
#5 | Shi Zhe | 6 |
#6 | Han Zixing | 6 |
#7 | Tao Liangshan | 6 |
#8 | Wang Yaolin | 6 |
#9 | Niu Haotao | 3 |
#10 | Weng Jifang | 3 |
Publication | Filing date | Title |
---|---|---|
WO2020233592A1 | Heterocyclic compounds, preparation methods and uses thereof | |
WO2020228807A1 | Salts of a class of pyrimidine compounds, polymorphs, and pharmaceutical compositions thereof, preapration methods therefor and uses thereof | |
WO2020073974A1 | Thyroid hormone receptor agonists | |
WO2020258006A1 | Heterocyclic compounds, preparation methods therefor, and methods of uses thereof | |
CN112119074A | EGFR inhibitors | |
WO2020132785A1 | Novel salts of selective estrogen receptor degraders | |
WO2020124397A1 | C-terminal src kinase inhibitors | |
WO2019183835A1 | Novel salt forms of urat-1 inhibitors | |
KR20170101908A | Pyrimidine or pyridine compounds, preparation method therefor and pharmaceutical uses thereof | |
EP3181557A1 | Carboxylic acid compound, method for preparation thereof, and use thereof |